Adamas Pharmaceuticals Inc (ADMS) Given Consensus Recommendation of “Buy” by Analysts

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has earned a consensus recommendation of “Buy” from the twelve brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $45.67.

Several equities research analysts recently weighed in on ADMS shares. ValuEngine upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Piper Jaffray Companies restated an “overweight” rating and set a $30.00 target price on shares of Adamas Pharmaceuticals in a report on Wednesday, September 20th. Mizuho restated a “buy” rating and set a $48.00 target price (up from $26.00) on shares of Adamas Pharmaceuticals in a report on Wednesday, September 13th. Needham & Company LLC restated a “buy” rating and set a $38.00 target price on shares of Adamas Pharmaceuticals in a report on Sunday, September 17th. Finally, Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in shares of Adamas Pharmaceuticals in the 3rd quarter worth approximately $110,000. Quantbot Technologies LP bought a new position in Adamas Pharmaceuticals during the 3rd quarter valued at approximately $119,000. Tower Research Capital LLC TRC bought a new position in Adamas Pharmaceuticals during the 2nd quarter valued at approximately $109,000. Sei Investments Co. increased its position in Adamas Pharmaceuticals by 1,105.0% during the 3rd quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock valued at $185,000 after buying an additional 8,033 shares in the last quarter. Finally, Virtu KCG Holdings LLC bought a new position in Adamas Pharmaceuticals during the 2nd quarter valued at approximately $184,000. Institutional investors and hedge funds own 79.40% of the company’s stock.

Shares of Adamas Pharmaceuticals (ADMS) traded up $0.13 during trading on Monday, hitting $34.40. The stock had a trading volume of 691,700 shares, compared to its average volume of 552,751. The company has a debt-to-equity ratio of 0.41, a current ratio of 8.35 and a quick ratio of 8.32. The company has a market cap of $786.57, a price-to-earnings ratio of -10.24 and a beta of 1.13. Adamas Pharmaceuticals has a 12-month low of $13.50 and a 12-month high of $38.22.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.03). Adamas Pharmaceuticals’s revenue for the quarter was down 99.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.66) earnings per share. analysts expect that Adamas Pharmaceuticals will post -3.84 EPS for the current year.

WARNING: “Adamas Pharmaceuticals Inc (ADMS) Given Consensus Recommendation of “Buy” by Analysts” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/25/adamas-pharmaceuticals-inc-adms-given-consensus-recommendation-of-buy-by-analysts.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit